Short Interest in Synaptogenix, Inc. (NASDAQ:SNPX) Expands By 162.8%

Synaptogenix, Inc. (NASDAQ:SNPX) saw a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 11,300 shares, a growth of 162.8% from the May 15th total of 4,300 shares. Based on an average daily volume of 724,900 shares, the short-interest ratio is currently 0.0 days. Currently, 0.8% of the shares of the stock are short sold.

Synaptogenix Stock Performance

Shares of SNPX opened at $3.71 on Friday. The company’s fifty day moving average is $2.50 and its 200 day moving average is $2.81. The stock has a market capitalization of $5.16 million, a PE ratio of -0.37 and a beta of 1.08. Synaptogenix has a fifty-two week low of $1.84 and a fifty-two week high of $5.52.

Synaptogenix (NASDAQ:SNPX) last posted its quarterly earnings data on Thursday, May 15th. The company reported $0.04 EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Synaptogenix stock. Geode Capital Management LLC acquired a new position in shares of Synaptogenix, Inc. (NASDAQ:SNPX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned 0.80% of Synaptogenix as of its most recent SEC filing. Institutional investors own 10.34% of the company’s stock.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.